

1  
2  
3  
4 **Impact of sleep habits on life expectancy free of cardiovascular disease in the**  
5 **Chinese population: a prospective cohort study**  
6

7 Qiufen Sun PhD<sup>1,2</sup>, Jingcen Hu BM<sup>1</sup>, Canqing Yu PhD<sup>1,3,4</sup>, Dianjianyi Sun PhD<sup>1,3,4</sup>,  
8 Pei Pei BSc<sup>3</sup>, Ling Yang PhD<sup>5</sup>, Yiping Chen DPhil<sup>5</sup>, Huaidong Du PhD<sup>5</sup>, Xiaofang  
9 Zhang AD<sup>6</sup>, Dan Schmidt MSc<sup>5</sup>, Prof Junshi Chen MD<sup>7</sup>, Prof Zhengming Chen  
10 DPhil<sup>5</sup>, Prof Liming Li MPH<sup>1,3,4\*</sup>, Prof Jun Lv PhD<sup>1,3,4,8\*</sup>, on behalf of the China  
11 Kadoorie Biobank Collaborative Group<sup>†</sup>  
12  
13  
14  
15  
16

- 17  
18 1. Department of Epidemiology & Biostatistics, School of Public Health, Peking  
19 University, Beijing 100191, China;  
20  
21 2. Department of Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention  
22 and Treatment, Collaborative Innovation Center for Cancer Personalized  
23 Medicine, School of Public Health, Nanjing Medical University, Nanjing,  
24 Jiangsu, China;  
25  
26 3. Peking University Center for Public Health and Epidemic Preparedness &  
27 Response, Beijing 100191, China;  
28  
29 4. Key Laboratory of Epidemiology of Major Diseases (Peking University),  
30 Ministry of Education, Beijing 100191, China  
31  
32 5. Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield  
33 Department of Population Health, University of Oxford, United Kingdom  
34  
35 6. NCDs Prevention and Control Department, Maiji CDC, Tianshui, Gansu, China  
36  
37 7. China National Center for Food Safety Risk Assessment, Beijing, 100022, China  
38  
39 8. State Key Laboratory of Vascular Homeostasis and Remodeling, Peking  
40 University, Beijing 100191, China  
41  
42  
43  
44  
45  
46

47 **\*Correspondence to:**

48 Jun Lv, PhD

49 Department of Epidemiology and Biostatistics, Peking University Health Science  
50 Center  
51

52 38 Xueyuan Road, Beijing 100191, China

53 Phone: 86-10-82801528

54 Email: [lvjun@bjmu.edu.cn](mailto:lvjun@bjmu.edu.cn)  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Liming Li, MD, MPH

Department of Epidemiology and Biostatistics, Peking University Health Science

Center

38 Xueyuan Road, Beijing 100191, China

Phone: 86-10-82801528

Email: [lmlee@vip.163.com](mailto:lmlee@vip.163.com)

†The members of steering committee and collaborative group are listed in the online-only supplemental material.

**Word count of main text:** 4,506

(5 figures, 1 table, and 1 Supplementary material)

## Abstract

### Background

Abnormal sleep duration and poor sleep quality have been associated with increased risks of cardiovascular disease (CVD) incidence and mortality. However, little is known about how these sleep problems affect total life expectancy (LE) and LE free of CVD and its subtypes.

### Methods

We included 483,384 adults from the China Kadoorie Biobank (CKB) who were free of heart disease, stroke, cancer, major depressive disorder, and generalized anxiety disorder at baseline. Sleep duration was categorized as <6 h/d, 6-9 h/d, and >9 h/d. Three sleep disturbance symptoms were considered: self-reported difficulties initiating and maintaining sleep, early morning awakening, and daytime dysfunction. Participants with at least one of the three symptoms were considered to have a sleep disturbance. We estimated sex-specific LE with and without CVD at age 40 by using multistate Markov models, with separate models specified for total CVD, ischemic heart disease (IHD), ischemic stroke (IS), and hemorrhagic stroke (HS) as the disease state.

### Results

During a median follow-up of 12.1 years, we documented 135,429 incident CVD events, including 46,479 IHD events, 47,562 IS events, and 10,844 HS events. Overall, there

1  
2  
3  
4 were 48,372 deaths. Compared to other sleep problems, longer sleep duration (>9 h/d)  
5  
6 had the greatest impact on total LE and LE free of CVD and its subtypes, with the  
7  
8 impact on total LE greater than that of disease-free LE. In men, the reduction in total  
9  
10 LE and LE without CVD (95% confidence intervals) at age 40 associated with longer  
11  
12 sleep duration was 2.11 (-2.50, -1.71) and 1.29 (-1.68, -0.98) years, respectively. The  
13  
14 corresponding values for women were 1.37 (-1.81, -0.98) and 0.43 (-0.75, -0.07) years.  
15  
16  
17 In contrast, sleep disturbance had a stronger impact on disease-free LE than on total  
18  
19 LE, thereby reducing the proportion of life spent in a healthy state. Compared with  
20  
21 participants without sleep disturbance, the total LE at age 40 was 0.46 (-0.77, -0.15)  
22  
23 and 0.22 (-0.47, 0.06) years lower in men and women with sleep disturbance,  
24  
25 respectively, and the LE without CVD was 0.99 (-1.23, -0.73) and 1.05 (-1.27, -0.85)  
26  
27 years lower.  
28  
29  
30  
31  
32  
33  
34  
35

## 36 **Conclusions**

37  
38  
39  
40 In this Chinese population, abnormal sleep duration, especially long sleep, and sleep  
41  
42 disturbance were linked with lower total LE and LE free of CVD. This study confirmed  
43  
44 the importance of good sleep habits in health management for both those without and  
45  
46 with CVD.  
47  
48  
49

## 50 **Keywords**

51  
52  
53  
54  
55 Sleep duration, sleep quality, disease-free life expectancy, cardiovascular disease,  
56  
57 cohort study  
58  
59  
60

## Introduction

Sleep accounts for one-third of a person's life, and getting adequate and good-quality sleep is critical for health and well-being. In recent years, insufficient sleep and poor sleep quality have emerged as a global health concern. For example, more than one-quarter of the population in most European countries suffers from insomnia,<sup>1</sup> while at least one-third of Americans sleep less than 7 hours per day.<sup>2</sup> Such sleep problems are common in the Chinese population as well.<sup>3</sup>

Previous studies found that abnormal sleep duration, whether short or long, and poor sleep quality were both associated with an increased risk of total cardiovascular disease (CVD), coronary heart disease, and stroke, but the impact on coronary heart disease and stroke may differ.<sup>4-7</sup> A few studies conducted separately in patients with different types of CVD have also found an association between abnormal sleep duration and an increased risk of mortality in patients with CVD.<sup>8,9</sup> Furthermore, the aforementioned sleep problems have been linked to an increased risk of all-cause mortality in the general population.<sup>10-12</sup>

Unlike commonly used ratio-based estimates such as relative risk, life expectancy (LE) free of disease measures the average number of years lived without disease by combining both morbidity and mortality, providing an intuitive metric for evaluating the burdens related to specific risk factors. For example, if we define disease state of interest as having CVD, total life years can be divided into those lived without and with CVD, termed CVD-free LE and LE with CVD, respectively. The CVD-free LE is

1  
2  
3  
4 determined by the CVD incidence risk and mortality risk in the absence of CVD,  
5  
6 whereas LE with CVD is determined by the CVD incidence risk and mortality risk in  
7  
8 the presence of CVD.<sup>13</sup> However, because study populations, exposure definitions or  
9  
10 classifications, and statistical analysis methods vary among existing studies, we could  
11  
12 not clarify the impact of the aforementioned sleep problems on total LE and LE free of  
13  
14 CVD and its subtypes simply by comparing the results of different studies.  
15  
16  
17  
18  
19

20  
21 To date, only one study using the UK Biobank (UKB) has evaluated the impact of sleep  
22  
23 problems on total LE and LE free of CVD.<sup>14</sup> The study defined shorter sleep duration  
24  
25 (<7 h/d) or longer sleep duration ( $\geq 9$  h/d) as suboptimal sleep duration. Participants  
26  
27 with different sleep characteristics had similar total LE, but those with suboptimal sleep  
28  
29 duration and/or insomnia had a significant reduction in LE free of CVD. Nevertheless,  
30  
31 this study did not report the strength of the association between sleep problems and  
32  
33 each stage of CVD development and progression, making it hard to determine whether  
34  
35 sleep problems contributed to the reduction of CVD-free LE by influencing which stage  
36  
37 of disease progression. Furthermore, it is unclear whether longer and shorter sleep  
38  
39 durations have different impacts on CVD-free LE, whether the impact of various sleep  
40  
41 problems on LE free of different CVD subtypes are consistent, and whether the findings  
42  
43 in the UK population are applicable to the Chinese population.  
44  
45  
46  
47  
48  
49  
50  
51

52  
53 Thus, in this study, based on the China Kadoorie Biobank (CKB) of 0.5 million adults,  
54  
55 we aimed to examine the impact of sleep duration and various sleep disturbance  
56  
57 symptoms on the development and progression of total CVD and its subtypes, as well  
58  
59  
60

1  
2  
3  
4 as differences in CVD-free LE and its share of total LE in participants with different  
5  
6 sleep characteristics.  
7  
8

## 9 10 **Methods**

### 11 12 13 14 **Study design and participants**

15  
16  
17  
18 The CKB is a nationwide population-based prospective cohort study. The study  
19  
20 design and implementation are detailed elsewhere.<sup>15</sup> In brief, the 2004-2008 baseline  
21  
22 survey enrolled 512,723 participants aged 30-79 from five urban and five rural areas.  
23  
24 Following the completion of the baseline survey, all participants were followed up for  
25  
26 mortality, morbidity, and hospitalization events. Two periodic resurveys were  
27  
28 conducted in 2008 and 2013-2014, each with a cluster random sample of about 5%  
29  
30 surviving participants. To avoid missing items and minimize logic errors, information  
31  
32 collected at baseline and resurveys was directly entered into a laptop-based data entry  
33  
34 system with built-in functions. All participants signed an informed consent form. The  
35  
36 Ethical Review Committee of the Chinese Center for Disease Control and Prevention  
37  
38 (Beijing, China), the Peking University Health Science Center (Beijing, China), and  
39  
40 the Oxford Tropical Research Ethics Committee, University of Oxford (UK) approved  
41  
42 the study.  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53 In the present study, we excluded participants with self-reported clinician diagnoses  
54  
55 of coronary heart disease (n=15,472), stroke (n=8,884), or cancer (n=2,578) at  
56  
57 baseline. We also excluded participants who had major depressive disorder (n=3,354)  
58  
59  
60

1  
2  
3  
4 or generalized anxiety disorder (n=1,278), as determined by section A and section B  
5  
6 of the Chinese version of the computerized Composite International Diagnostic  
7  
8 Inventory-short form, respectively.<sup>16</sup> This exclusion was implemented to minimize  
9  
10 potential confounding by psychological conditions. Reasons for exclusion were not  
11  
12 mutually exclusive. Forty-eight participants with missing values for body mass index  
13  
14 (BMI) or women's menopause status were also excluded, leaving 483,384 participants  
15  
16 in the primary analysis.  
17  
18  
19  
20  
21

### 22 23 **Assessment of sleep behaviors and other covariates**

24  
25  
26  
27 Sleep behaviors were assessed by an interviewer-administered questionnaire. By  
28  
29 asking, "How many hours do you typically sleep per day (including naps)?" sleep  
30  
31 duration was recorded as the number of reported hours. Based on the American  
32  
33 National Sleep Foundation's sleep time recommendation, sleep duration was  
34  
35 categorized as <6 h/d, 6-9 h/d, and >9 h/d.<sup>17</sup> Participants were asked if they had any of  
36  
37 the following symptoms of sleep disturbance for at least 3 days per week in the past  
38  
39 month (yes or no): (1) sleep onset latency of  $\geq 30$  min after going to bed or waking up  
40  
41 in the middle of the night: if yes, considered as having difficulties initiating and  
42  
43 maintaining sleep (DIMS); (2) waking up early and not being able to go back to sleep:  
44  
45 if yes, considered as having disorders of early morning awakening (EMA); (3) having  
46  
47 difficulty staying alert while at work, eating or meeting people during daytime: if yes,  
48  
49 considered as having daytime dysfunction (DDF). Participants who reported having  
50  
51 one or more of the three aforementioned conditions were considered to have a sleep  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 disturbance.<sup>18</sup>  
5  
6  
7

8 Other covariates, including socio-demographic characteristics, lifestyle behaviors,  
9  
10 personal and family medical history, and women's menopausal status, were assessed  
11  
12 by questionnaire and physical measurements. Participants who had at least one first-  
13  
14 degree relative, including biological parents and siblings, having a heart attack or  
15  
16 stroke were considered as having a CVD family history. The physical activity level  
17  
18 was calculated by multiplying the metabolic equivalent of task (MET) value of each  
19  
20 type of activity and the hours spent on that activity per day and then summarizing the  
21  
22 MET-hours for all activities.<sup>19</sup> Habitual dietary intake in the past year was assessed by  
23  
24 a qualitative food frequency questionnaire.<sup>20</sup> Weight and height were measured by  
25  
26 trained staff using well-calibrated instruments. BMI was calculated as weight in  
27  
28 kilograms divided by height in meters squared. Prevalent hypertension was defined as  
29  
30 measured systolic blood pressure  $\geq 140$  mmHg, measured diastolic blood pressure  $\geq 90$   
31  
32 mmHg, self-reported diagnosis of hypertension, or self-reported use of  
33  
34 antihypertensive medication at baseline. Prevalent diabetes was defined as self-  
35  
36 reported diabetes or a measured fasting blood glucose  $\geq 7.0$  mmol/L or random blood  
37  
38 glucose  $\geq 11.1$  mmol/L at baseline.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

#### 50 **Ascertainment of disease onset and deaths**

51  
52  
53

54 Incident cases of interest and the vital status of each participant were identified chiefly  
55  
56 by linking to local disease and death registries and national health insurance database,  
57  
58 supplemented with annual active follow-up to minimize loss to follow-up. All events  
59  
60

1  
2  
3  
4 were coded according to the 10th revision of the International Classification of  
5  
6 Diseases (ICD-10) by trained staff blinded to the baseline information.  
7  
8

9  
10 The disease outcomes of interest in this study were CVD (I00-I99) and its major  
11  
12 component endpoints -- ischemic heart disease (IHD, I20-I25), ischemic stroke (IS,  
13  
14 I63), and hemorrhagic stroke (HS, I61). Case adjudication for IHD and stroke has  
15  
16 been ongoing since 2014. Qualified cardiovascular specialists who were not aware of  
17  
18 the baseline exposures reviewed the medical records of incident cases. Of the 33,515  
19  
20 medical records of IHD cases and 40,465 medical records of stroke cases retrieved by  
21  
22 October 2018, 87.9% of IHD cases and 91.8% of stroke cases had their diagnosis  
23  
24 confirmed.<sup>21</sup>  
25  
26  
27  
28  
29

### 30 31 32 **Statistical analysis** 33

34  
35 Changes in sleep behaviors between the 2004-2008 baseline and 2013-2014 resurvey  
36  
37 by the occurrence of CVD during this period were analyzed with adjustments for age  
38  
39 at enrollment, sex, and study area, as appropriate.  
40  
41

42  
43  
44 The following analyses were performed for men and women separately. A multistate  
45  
46 Markov model was used to describe how participants moved between states in  
47  
48 continuous time. To estimate associations between sleep behaviors and the  
49  
50 instantaneous risk of movement between states, we constructed a non-recoverable  
51  
52 illness-death model, with participants starting free of disease and moving (1) from  
53  
54 disease-free to presence of disease; (2) from disease-free to death without  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 experiencing the disease. Participants could also move from a disease state to death.  
5  
6 Only the first entry into a state was considered. For participants who died on the same  
7  
8 date as their first diagnosis, we used the date of death minus 0.5 days as the date of  
9  
10 disease onset.<sup>22</sup> Separate models were specified for CVD, IHD, IS, and HS as the  
11  
12 disease state.  
13  
14

15  
16  
17 Age was used as the time scale for all models. Participants were considered at risk  
18  
19 from enrollment to death, loss to follow-up, or 31 December 2018, whichever came  
20  
21 first. The parameters of the three-state model were estimated as a log-linear  
22  
23 parametric model with an exponential distribution using the msm R package.<sup>23</sup> The  
24  
25 analytical model included sleep behaviors and covariates, including attained age,  
26  
27 study areas, education, marital status, family history of CVD, smoking status, alcohol  
28  
29 intake, physical activity, dietary factors (intake frequencies of fresh vegetables, fresh  
30  
31 fruits, and red meat), BMI, and menopausal status (only in women). All covariates  
32  
33 were time-constant and influenced the instantaneous risk of movement between states  
34  
35 in a proportional hazard manner.  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 With the estimated parameters of the multistate model above, LE at age 40 years was  
46  
47 calculated using the Estimating Life Expectancies in Continuous Time (ELECT) R  
48  
49 package (version 1.2).<sup>24</sup> The upper limit was set as 90 years since few participants  
50  
51 reached this age during the follow-up period. For all the LE estimations, covariates  
52  
53 used in analytic models were specified to the baseline average levels of the cohort.  
54  
55  
56 The confidence intervals (CIs) for LE were estimated using simulation 500 times.<sup>25</sup>  
57  
58  
59  
60

To examine the robustness of the results, we performed several sensitivity analyses:

(1) further adjusting for prevalence of hypertension and diabetes, and usage of statin at baseline; (2) excluding participants with chronic obstructive pulmonary disease (COPD), asthma, or type 2 diabetes (T2D) at baseline; (3) excluding participants who experienced disease onset or died within the first five years of follow-up.

Subgroup analyses were performed by residence (urban or rural), baseline disease status (with hypertension and/or diabetes, or none), family history of CVD (with or without), smoking status (never, former, and current; only in men), and physical activity level (age-specific [ $<50$ ,  $50-59$ , and  $\geq 60$  years] and sex-specific median or higher level, or lower level). All statistical analyses were performed using R version 4.0.3.

## Results

### Characteristics of the study population

The mean age of the included 483,384 participants was  $51.5 \pm 10.6$  years, and 41.0% were men. At baseline, 86.9% of participants slept between 6 and 9 hours per day, while 8.0% slept less than 6 hours and 5.1% slept more than 9 hours; additionally, 16.1% of participants reported at least one symptom of sleep disturbance. Overall, participants who were older, less-educated, or lived in rural areas were more likely to have shorter or longer sleep duration, as well as sleep disturbance (**Table 1**). Of the 23,932 participants who participated in the 2013-2014 resurvey, over 70% had not

1  
2  
3  
4 changed their sleep habits since baseline (**Supplementary Table 1**). In addition, there  
5  
6 were no discernible differences in sleep habit changes between participants who  
7  
8 experienced CVD events and those who did not.  
9

10  
11  
12  
13 During a median follow-up of 12.1 years (5.69 million person-years, PYs), 135,429  
14  
15 incident CVD events were documented, with 46,479 being IHD events, 47,562 being  
16  
17 IS events, and 10,844 being HS events. We recorded 48,372 deaths, 18,740 of which  
18  
19 had no documented CVD between baseline and death.  
20  
21  
22

### 23 24 **Sleep behaviors and transitions between states**

25  
26  
27  
28 After controlling for potential confounders, shorter sleep duration was not associated  
29  
30 with the incidence risks of CVD or any of the subtypes, nor with the mortality risk in  
31  
32 the absence of disease, except that the risks of CVD and IHD onset were slightly  
33  
34 increased in women with shorter sleep duration (**Figures 1 and 2**). In contrast, shorter  
35  
36 sleep duration was associated with increased mortality risks in the presence of CVD  
37  
38 or any of the subtypes in men and HS in women. The strongest association was  
39  
40 observed for HS, with HRs (95% confidence intervals [CIs]) of 1.28 (1.13, 1.43) and  
41  
42 1.21 (1.09, 1.36) for men and women, respectively.  
43  
44  
45  
46  
47  
48  
49

50  
51 Longer sleep duration was associated with elevated risks of almost all transitions. In  
52  
53 men, compared with participants with a sleep duration of 6-9 h/d, the HRs (95% CIs)  
54  
55 of those with longer sleep duration were 1.13 (1.09, 1.18), 1.07 (0.99, 1.16), and 1.29  
56  
57 (1.22, 1.37) for baseline to CVD onset, baseline to death, and disease to death,  
58  
59  
60

1  
2  
3  
4 respectively. The corresponding values for women were 1.03 (0.99, 1.06), 1.16 (1.05,  
5  
6 1.29), and 1.21 (1.12, 1.31). In general, the association of longer sleep duration with  
7  
8 mortality risk in the presence of disease was stronger than that with incidence risk.

9  
10  
11 Except in men, longer sleep duration was associated with an elevated incidence risk of  
12  
13 HS, with an HR (95% CI) of 1.33 (1.21, 1.48), but was not with the mortality risk in  
14  
15 the presence of disease.  
16  
17

18  
19  
20  
21 Except for HS, sleep disturbance was associated with increased incidence risks of  
22  
23 CVD and all subtypes. However, there was no statistically significant association  
24  
25 between sleep disturbance and most transitions to death. Compared with participants  
26  
27 without sleep disturbance, the HRs (95% CIs) for CVD onset in men and women with  
28  
29 sleep disturbance were 1.10 (1.07, 1.13) and 1.10 (1.08, 1.13), respectively. When  
30  
31 individual symptoms of sleep disturbance were considered, the results were largely  
32  
33 consistent; except that EMA was not associated with the incidence risks of CVD or  
34  
35 any of the subtypes in men (**Supplementary Table 2**).  
36  
37  
38  
39  
40  
41

#### 42 **Sleep behaviors and LE with and without disease**

43  
44  
45  
46 Longer sleep duration basically had a greater impact on total LE and disease-free LE  
47  
48 for CVD, IHD, and IS at age 40 than shorter sleep duration in both men and women  
49  
50 (**Figures 3 and 4**). In men, the reduction in total LE caused by longer or shorter  
51  
52 duration was greater than the reduction in disease-free LE. In the analysis of CVD, the  
53  
54 total LE of 40-year-old men with longer or shorter sleep duration was reduced by 2.11  
55  
56 (-2.50, -1.71) and 0.72 (-1.09, -0.39) years, respectively, with the reduction in LE  
57  
58  
59  
60

1  
2  
3  
4 without CVD being 1.29 (-1.68, -0.98) and 0.27 (-0.61, 0.05) years. In women, only  
5  
6 longer sleep duration was similarly linked to a reduction in total LE and CVD-free LE  
7  
8 at age 40 of 1.37 (-1.81, -0.98) and 0.43 (-0.75, -0.07) years, respectively. In contrast,  
9  
10 disease-free LE was reduced more than total LE in women with shorter sleep  
11  
12 duration, or both were approximate.  
13  
14  
15

16  
17  
18 Sleep disturbance had a greater impact on LE without CVD, IHD, and IS than on total  
19  
20 LE at age 40 in both men and women, with a consequent reduction in the proportion  
21  
22 of disease-free LE to total LE. Compared with participants without sleep disturbance,  
23  
24 the total LE at age 40 was 0.46 (-0.77, -0.15) and 0.22 (-0.47, 0.06) years lower in  
25  
26 men and women with sleep disturbance, respectively, and LE without CVD was 0.99  
27  
28 (-1.23, -0.73) and 1.05 (-1.27, -0.85) years lower.  
29  
30  
31  
32

33  
34  
35 The impacts of longer and shorter sleep duration, as well as sleep disturbance, on LE  
36  
37 without HS were similar to total LE at age 40 in both men and women. Compared  
38  
39 with the reference group, the number of years lived free of HS at age 40 for  
40  
41 participants with longer and shorter sleep duration and sleep disturbance was 2.08 (-  
42  
43 2.60, -1.68), 0.49 (-0.91, -0.11) and 0.47 (-0.80, -0.15) years lower in men,  
44  
45 respectively. The corresponding estimates in women were 1.43 (-1.89, -0.96), 0.24 (-  
46  
47 0.58, 0.05), and 0.29 (-0.58, -0.03) years.  
48  
49  
50  
51  
52

53  
54 Sensitivity analyses revealed no significant changes in the results (**Supplementary**  
55  
56 **Tables 3 and 4**). Similar findings were found for CVD-free LE at ages 40, 50, and 65  
57  
58 (**Supplementary Table 5**). When symptoms of sleep disturbance were considered  
59  
60

1  
2  
3  
4 individually, only DIMS had a statistically significant impact on total LE and disease-  
5  
6 free LE in men; in women, all symptoms of sleep disturbance had impacts on disease-  
7  
8 free LE, except for HS (**Supplementary Figures 1 and 2**).

9  
10  
11  
12  
13 In the joint analysis, compared with those with a sleep duration of 6-9 h/d and no  
14  
15 sleep disturbance, participants with longer sleep duration and sleep disturbance had  
16  
17 the greatest reduction in LE without CVD or any of the subtypes at age 40 (**Figure 5**).  
18  
19 The CVD-free LE was reduced by 1.99 (-3.50, -0.45) years in men and 1.86 (-3.22, -  
20  
21 0.64) years in women.  
22  
23  
24  
25

26  
27 In the subgroup analysis by residence, the impact of longer sleep duration and sleep  
28  
29 disturbance on LE without disease was slightly greater among urban residents than  
30  
31 rural residents for most outcomes (**Supplementary Figure 3**). Longer and shorter  
32  
33 sleep duration also had a greater impact on disease-free LE in participants with  
34  
35 prevalent hypertension or diabetes than in those without (**Supplementary Figure 4**).  
36  
37  
38  
39 Otherwise, the associations were broadly similar across subgroups defined by CVD  
40  
41 family history, smoking status, and physical activity level (**Supplementary Figures**  
42  
43  
44  
45 **5-7**).

## 46 47 48 49 **Discussion**

50  
51  
52  
53 This study found that longer sleep duration was associated with elevated risks of  
54  
55 incident CVD and its subtypes, as well as mortality risks either in the absence or in the  
56  
57 presence of disease, with the impact on mortality risks being stronger. Shorter sleep  
58  
59  
60

1  
2  
3  
4 duration was predominantly associated with an increased risk of mortality in the  
5  
6 presence of CVD, particularly in men. Sleep disturbance was associated with an  
7  
8 increased risk of CVD and its subtype incidence. Thus, longer sleep duration had a  
9  
10 bigger impact on total LE and LE free of CVD and its subtypes than both shorter sleep  
11  
12 duration and sleep disturbance; meanwhile, its impact on total LE was greater than that  
13  
14 of disease-free LE. In contrast, sleep disturbance had a stronger impact on LE free of  
15  
16 CVD and its subtypes than on total LE, with a consequent higher proportion of life  
17  
18 years lived with disease in participants with sleep disturbance.  
19  
20  
21  
22  
23  
24  
25

26 Only one study has evaluated the association between sleep behaviors and LE free of  
27  
28 CVD. Based on the UKB, the study found that men and women with only 0-1 healthy  
29  
30 sleep habits had a reduced CVD-free LE of 2.31 (95% CI: 1.46, 3.29) and 1.80 (0.96,  
31  
32 2.75) years at age 40, compared with those with 4-5 healthy sleep habits (sleep duration  
33  
34 of 7 to <9 h/d, no difficulty initiating or maintaining sleep, no snoring, morning  
35  
36 chronotype, no frequent daytime sleepiness).<sup>14</sup> Despite the slight difference in the  
37  
38 dimensions of sleep due to a different questionnaire design, the current study yielded  
39  
40 similar results. Compared with those with a sleep duration of 6-9 h/d and no symptoms  
41  
42 of sleep disturbance, the LE free of CVD at age 40 of participants with longer sleep  
43  
44 duration and any symptom of sleep disturbance was reduced by 1.99 (-3.50, -0.45) years  
45  
46 in men and 1.86 (-3.22, -0.64) years in women.  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 In the current study, longer sleep duration was associated with an increased risk of CVD  
57  
58 and its subtype incidence, as well as a deleterious impact on mortality risks in the  
59  
60

1  
2  
3  
4 absence or presence of disease, with a consequent significant reduction in both total LE  
5  
6 and LE free of disease. A meta-analysis of 95 prospective cohort studies showed that  
7  
8 participants with longer sleep duration had a 39% higher risk of all-cause mortality and  
9  
10 a 25% higher risk of CVD incidence risk compared with those with normal sleep  
11  
12 duration.<sup>26</sup> In this study, conducted in a single cohort, we also observed that those with  
13  
14 longer sleep duration had a greater increase in mortality risk than CVD incidence risk,  
15  
16 with a consequent bigger reduction in total LE than in CVD-free LE. It has been  
17  
18 postulated that the above association may be subjected to residual confounding or  
19  
20 reverse causation, as participants with longer sleep duration may be more fatigued, have  
21  
22 undiagnosed mental disorders, or be in a sub-healthy state.<sup>27,28</sup> However, in our primary  
23  
24 analysis, we only included participants without major chronic diseases, major  
25  
26 depressive disorder, or generalized anxiety disorder at baseline. Further excluding  
27  
28 participants with respiratory diseases or those who experienced disease onset or died  
29  
30 within the first 5 years of follow-up did not change the findings. This suggests that the  
31  
32 previously mentioned bias cannot fully explain the association between longer sleep  
33  
34 duration and the risk of CVD incidence or mortality. An earlier Mendelian  
35  
36 randomization (MR) study in UKB concluded that genetically predicted long sleep  
37  
38 duration might not be a causal risk factor for CVD, but this finding was likely  
39  
40 influenced by weak instrument bias.<sup>29</sup> There is still a need to discover more sleep-  
41  
42 related single nucleotide polymorphisms, and MR analysis in populations with different  
43  
44 genetic backgrounds is required for additional validation.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

57  
58  
59 Shorter sleep duration had a somewhat different impact on men and women, with men  
60

1  
2  
3  
4 having an increased risk of death after CVD disease and women having a little higher  
5  
6 incidence risk of CVD and IHD. As a result, women had a higher proportion of life  
7  
8 years lived with the disease. A few earlier studies also observed that shorter sleep  
9  
10 duration was associated with the elevated risks of CVD and its intermediate risk factors,  
11  
12 such as hypertension, atherosclerosis, and myocardial infarction, but only in women.<sup>30-</sup>  
13  
14  
15  
16  
17 <sup>33</sup> It was suggested that hormonal influences may play a role; for example, shorter sleep  
18  
19 duration may cause hormonal fluctuations in women, particularly around menopause,  
20  
21 when women are more vulnerable.<sup>32</sup> Nevertheless, midday napping might compensate  
22  
23 for the detrimental impact of shorter sleep duration at night in women.<sup>6</sup> The impact of  
24  
25 shorter sleep duration on mortality risk in the presence of CVD or its subtypes was only  
26  
27 seen in men, which was consistent with the findings of a recent study of 2,846 coronary  
28  
29 artery disease patients with a mean age of 64 years. In this US study, after a median  
30  
31 follow-up of 2.8 years, the all-cause mortality risk was only significantly increased in  
32  
33 men with shorter sleep duration compared with those with sleep duration of 6.5-7.4 h/d,  
34  
35 but not in women.<sup>9</sup> The reasons for this sex disparity are not fully understood.

36  
37  
38  
39  
40  
41  
42  
43  
44 In line with meta-analyses of the association between sleep disturbance and CVD  
45  
46 incidence risk and all-cause mortality,<sup>34,35</sup> we observed that sleep disturbance and all  
47  
48 its three symptoms were primarily associated with increased incidence risks of CVD,  
49  
50 IHD, and IS, but not with risk of most transitions to death. As a result, participants with  
51  
52 sleep disturbance developed CVD at a younger age and lived with it for a longer period  
53  
54 of time. In the above-mentioned UKB study, only women with DIMS or DDF showed  
55  
56 a significant reduction in CVD-free LE, with CVD-free LE at age 40 reduced by 0.30  
57  
58  
59  
60

1  
2  
3  
4 (0.18, 0.43) and 0.92 (0.04, 2.06) years, respectively.<sup>14</sup> In the current study, both men  
5  
6 and women suffered from the negative consequences. The LE free of CVD at age 40  
7  
8 was 0.67 (0.42, 0.93) and 1.29 (0.87, 1.74) years lower for participants with DIMS or  
9  
10 DDF, respectively in women; the corresponding values in men were 1.11 (0.79, 1.38)  
11  
12 and 0.74 (0.00, 1.49) years. Sleep disturbance had a greater impact on our population,  
13  
14 which may be partly related to the low treatment rate for insomnia in the Chinese  
15  
16 population. According to a survey conducted in northern China in 2018, only 2.1% of  
17  
18 participants with insomnia symptoms were treated, while only 6.2% of those with  
19  
20 clinical insomnia diagnosis.<sup>36</sup> However, in Western developed countries, the treatment  
21  
22 rate for insomnia symptoms reached 30% over a decade ago.<sup>37 38</sup> Proper insomnia  
23  
24 therapy may reduce the adverse effects on cardiovascular health.

25  
26  
27  
28  
29  
30  
31  
32  
33  
34 In the current study, except for longer sleep duration, which had a significant  
35  
36 association with an increased risk of HS incidence in men, none of the other sleep  
37  
38 problems was linked to the HS risk. The observed slight decrease in LE free of HS  
39  
40 among participants with shorter sleep duration or sleep disturbance was owing to an  
41  
42 increased mortality risk in the absence of HS. Only three previous studies investigated  
43  
44 the relationship between sleep duration and the risk of HS incidence, with two showing  
45  
46 no association,<sup>5,39</sup> and one revealing a link between longer sleep duration and a higher  
47  
48 risk of HS in women.<sup>40</sup> Because the number of HS cases in all these three studies was  
49  
50 less than 1,000, statistical power may be inadequate.

51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
This study has several strengths. First, using the same population and a uniform

1  
2  
3  
4 analytical strategy, we conducted the first comprehensive assessment of the impact of  
5  
6 longer and shorter sleep duration, as well as various symptoms of sleep disturbance, on  
7  
8 the development and progression of CVD and its subtypes. This could help us  
9  
10 understand how sleep problems affect total LE and LE free of disease. Second, the study  
11  
12 population was from areas with different economic development levels, having diverse  
13  
14 socioeconomic characteristics. Third, because of the large sample size and long-term  
15  
16 follow-up, the current study had greater statistical power to estimate disease-free LE  
17  
18 for CVD and its subtypes, as well as perform several subgroup analyses.  
19  
20  
21  
22  
23  
24  
25

26 Potential limitations should also be acknowledged. First, information on sleep duration  
27  
28 and sleep disturbance symptoms was self-reported. Thus, the results could be  
29  
30 influenced by information bias. Nevertheless, questionnaires are the most common and  
31  
32 feasible tool for large population-based studies, and self-reported information is also  
33  
34 the basis for assessing sleep quality in sleep clinics.<sup>41</sup> Second, we only used one baseline  
35  
36 measurement of sleep habits, and possible changes in sleep patterns during follow-up  
37  
38 were not considered. However, reverse causality could be avoided by using only  
39  
40 baseline information. Furthermore, among participants who attended both the baseline  
41  
42 survey and the second resurvey (a mean interval of 8 years), the changes in sleep  
43  
44 patterns were similar between those who developed CVD during this period and those  
45  
46 who did not. Third, limited by the questionnaire design, we focused on sleep duration  
47  
48 and quality while not including other characteristics of sleep, such as chronotype, which  
49  
50 is also an important factor in cardiovascular health.<sup>42</sup> However, some studies have  
51  
52 shown that chronotype was closely correlated with sleep duration.<sup>43,44</sup> Fourth, there is  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 a potential bidirectional relationship between sleep habits and CVD onset. However,  
5  
6 the study participants' inclusion criteria, as well as the sensitivity analyses used in this  
7  
8 study, suggest a robust temporal relationship between sleep habits and CVD onset.  
9  
10  
11 Nevertheless, the observational nature of this study limits causal inference, and future  
12  
13 MR studies with proper instrumental variables and adequate power are needed to test  
14  
15  
16 the association.  
17  
18  
19

20  
21 In conclusion, based on a large prospective cohort of Chinese adults, we revealed that  
22  
23 longer and shorter sleep duration, as well as sleep disturbance, had varied degrees of  
24  
25 negative influence on the incidence of CVD and its subtypes, as well as mortality in the  
26  
27 absence or the presence of CVD. Among them, longer sleep duration had the greatest  
28  
29 impact on total LE and LE free of CVD. The findings of this study confirm the  
30  
31 importance of good sleep habits in health management for individuals without and with  
32  
33 CVD. Further research could be performed to detect whether there are any mechanistic  
34  
35 pathways that mediate the adverse health effects of longer sleep duration. If their  
36  
37 association was causal, more effective interventions for longer sleep duration should be  
38  
39 developed.  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 **Contributors**

49  
50  
51 JL and LL conceived and designed the study, contributed to the interpretation of the  
52  
53 results and critical revision of the manuscript for valuable intellectual content. LL,  
54  
55 ZC, and JC: as the members of the CKB steering committee, designed and supervised  
56  
57 the conduct of the whole study, obtained funding, and together with CY, DS, PP, LY,  
58  
59  
60

1  
2  
3  
4 YC, HD, XZ, Dan S, acquired the CKB data. QS and JH accessed, verified, and  
5  
6 analyzed the data. QS drafted the manuscript. All authors had access to the data and  
7  
8 have read and approved the final manuscript. The corresponding author attests that all  
9  
10 listed authors meet authorship criteria and that no others meeting the criteria have  
11  
12 been omitted. JL and LL are the guarantors.  
13  
14  
15  
16  
17

### 18 **Declaration of interests**

19  
20  
21  
22 We declare no competing interests.  
23  
24

### 25 **Acknowledgments**

26  
27  
28  
29 The most important acknowledgment is to the participants in the study and the  
30  
31 members of the survey teams in each of the 10 regional centres, as well as to the  
32  
33 project development and management teams based at Beijing, Oxford and the 10  
34  
35 regional centres.  
36  
37  
38  
39

### 40 **Funding**

41  
42  
43  
44 This work was supported by National Natural Science Foundation of China  
45  
46 (82388102, 82192901, 82192900). The CKB baseline survey and the first re-survey  
47  
48 were supported by the Kadoorie Charitable Foundation in Hong Kong. The long-term  
49  
50 follow-up has been supported by Wellcome grants to Oxford University  
51  
52 (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and grants  
53  
54 (2016YFC0900500) from the National Key R&D Program of China, National Natural  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Science Foundation of China (81941018, 81390540, 91846303), and Chinese  
5  
6  
7 Ministry of Science and Technology (2011BAI09B01).  
8  
9

### 10 **Data availability**

11  
12  
13  
14 Details of how to access China Kadoorie Biobank data and details of the data release  
15  
16  
17 schedule are available from [www.ckbiobank.org/site/Data+Access](http://www.ckbiobank.org/site/Data+Access).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Baglioni C, Altena E, Bjorvatn B, et al. The European Academy for Cognitive Behavioural Therapy for Insomnia: An initiative of the European Insomnia Network to promote implementation and dissemination of treatment. *Journal of Sleep Research* 2020; **29**(2): e12967. <https://doi.org/10.1111/jsr.12967>
2. Centers for Disease Control and Prevention. Sleep and Sleep Disorders. <https://www.cdc.gov/sleep/index.html> (accessed September 7, 2022).
3. Yin P, Zhang M, Li Y, Jiang Y, Wang L, Zhao W. A study on risk factors for poor sleep quality among Chinese residents aged 15-69 years. *Chin J Prev Contr Chron Dis* 2011; **19**(3): 224-5.
4. Fan M, Sun D, Zhou T, et al. Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385 292 UK biobank participants. *Eur Heart J* 2020; **41**(11): 1182-9. <https://doi.org/10.1093/eurheartj/ehz849>
5. Zhou L, Yu K, Yang L, et al. Sleep duration, midday napping, and sleep quality and incident stroke: The Dongfeng-Tongji cohort. *Neurology* 2020; **94**(4): e345-e56. <https://doi.org/10.1212/wnl.00000000000008739>
6. Wang C, Bangdiwala SI, Rangarajan S, et al. Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. *Eur Heart J* 2019; **40**(20): 1620-9. <https://doi.org/10.1093/eurheartj/ehy695>
7. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective

- 1  
2  
3  
4 studies. *Eur Heart J* 2011; **32**(12): 1484-92.<https://doi.org/10.1093/eurheartj/ehr007>  
5  
6  
7 8. McDermott MM, Guralnik JM, Ferrucci L, et al. Community walking speed,  
8  
9 sedentary or lying down time, and mortality in peripheral artery disease. *Vasc Med* 2016;  
10  
11 **21**(2): 120-9.<https://doi.org/10.1177/1358863x15626521>  
12  
13  
14 9. Kim JH, Hayek SS, Ko YA, et al. Sleep Duration and Mortality in Patients With  
15  
16 Coronary Artery Disease. *Am J Cardiol* 2019; **123**(6): 874-  
17  
18 81.<https://doi.org/10.1016/j.amjcard.2018.11.057>  
19  
20  
21  
22 10. Liang YY, Ai S, Xue H, et al. Joint Associations of Device-Measured Sleep  
23  
24 Duration and Efficiency With All-Cause and Cause-Specific Mortality: A Prospective  
25  
26 Cohort Study of 90 398 UK Biobank Participants. *J Gerontol A Biol Sci Med Sci* 2023;  
27  
28 **78**(9): 1717-24.<https://doi.org/10.1093/gerona/glad108>  
29  
30  
31  
32 11. Mahmood A, Ray M, Ward KD, Dobalian A, Ahn S. Longitudinal associations  
33  
34 between insomnia symptoms and all-cause mortality among middle-aged and older  
35  
36 adults: a population-based cohort study. *Sleep* 2022;  
37  
38 **45**(6).<https://doi.org/10.1093/sleep/zsac019>  
39  
40  
41  
42 12. Wang YH, Wang J, Chen SH, et al. Association of Longitudinal Patterns of  
43  
44 Habitual Sleep Duration With Risk of Cardiovascular Events and All-Cause Mortality.  
45  
46 *JAMA Netw Open* 2020; **3**(5):  
47  
48 e205246.<https://doi.org/10.1001/jamanetworkopen.2020.5246>  
49  
50  
51  
52 13. Schoen R. Modeling multigroup populations: Springer Science & Business Media;  
53  
54 2013.  
55  
56  
57  
58 14. Huang BH, Del Pozo Cruz B, Teixeira-Pinto A, Cistulli PA, Stamatakis E.  
59  
60

- 1  
2  
3  
4 Influence of poor sleep on cardiovascular disease-free life expectancy: a multi-  
5  
6 resource-based population cohort study. *BMC Med* 2023; **21**(1):  
7  
8  
9 75.<https://doi.org/10.1186/s12916-023-02732-x>  
10  
11  
12 15. Chen Z, Chen J, Collins R, et al. China Kadoorie Biobank of 0.5 million people:  
13  
14 survey methods, baseline characteristics and long-term follow-up. *International journal*  
15  
16 *of epidemiology* 2011; **40**(6): 1652-66.<https://doi.org/10.1093/ije/dyr120>  
17  
18  
19 16. Chen Y, Kartsonaki C, Clarke R, et al. Characteristics and correlates of sleep  
20  
21 duration, daytime napping, snoring and insomnia symptoms among 0.5 million Chinese  
22  
23 men and women. *Sleep Medicine* 2018; **44**: 67-  
24  
25  
26 75.<https://doi.org/https://doi.org/10.1016/j.sleep.2017.11.1131>  
27  
28  
29 17. Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation's sleep  
30  
31 time duration recommendations: methodology and results summary. *Sleep Health* 2015;  
32  
33 **1**(1): 40-3.<https://doi.org/10.1016/j.sleh.2014.12.010>  
34  
35  
36 18. Sun X, Zheng B, Lv J, et al. Sleep behavior and depression: Findings from the  
37  
38 China Kadoorie Biobank of 0.5 million Chinese adults. *J Affect Disord* 2018; **229**: 120-  
39  
40  
41 4.<https://doi.org/10.1016/j.jad.2017.12.058>  
42  
43  
44 19. Du H, Bennett D, Li L, et al. Physical activity and sedentary leisure time and their  
45  
46 associations with BMI, waist circumference, and percentage body fat in 0.5 million  
47  
48 adults: the China Kadoorie Biobank study. *Am J Clin Nutr* 2013; **97**(3): 487-  
49  
50  
51 96.<https://doi.org/10.3945/ajcn.112.046854>  
52  
53  
54 20. Zhu N, Yu C, Guo Y, et al. Adherence to a healthy lifestyle and all-cause and cause-  
55  
56 specific mortality in Chinese adults: a 10-year prospective study of 0.5 million people.  
57  
58  
59  
60

- 1  
2  
3  
4 *The international journal of behavioral nutrition and physical activity* 2019; **16**(1):  
5  
6 98.<https://doi.org/10.1186/s12966-019-0860-z>  
7  
8  
9 21. Han Y, Hu Y, Yu C, et al. Lifestyle, cardiometabolic disease, and multimorbidity  
10  
11 in a prospective Chinese study. *European heart journal* 2021; **42**(34): 3374-  
12  
13 84.<https://doi.org/10.1093/eurheartj/ehab413>  
14  
15  
16 22. Sun Q, Hu Y, Yu C, et al. Healthy lifestyle and life expectancy free of major  
17  
18 chronic diseases at age 40 in China. *Nature Human Behaviour*  
19  
20 2023.<https://doi.org/10.1038/s41562-023-01624-7>  
21  
22  
23 23. Jackson C. Multi-State Models for Panel Data: The msm Package for R. *Journal of*  
24  
25 *Statistical Software* 2011; **38**(8): 1 - 28.<https://doi.org/10.18637/jss.v038.i08>  
26  
27  
28 24. van den Hout A, Sum Chan M, Matthews F. Estimation of life expectancies using  
29  
30 continuous-time multi-state models. *Comput Methods Programs Biomed* 2019; **178**:  
31  
32 11-8.<https://doi.org/10.1016/j.cmpb.2019.06.004>  
33  
34  
35 25. O'Doherty MG, Cairns K, O'Neill V, et al. Effect of major lifestyle risk factors,  
36  
37 independent and jointly, on life expectancy with and without cardiovascular disease:  
38  
39 results from the Consortium on Health and Ageing Network of Cohorts in Europe and  
40  
41 the United States (CHANCES). *European journal of epidemiology* 2016; **31**(5): 455-  
42  
43 68.<https://doi.org/10.1007/s10654-015-0112-8>.  
44  
45  
46 26. Jike M, Itani O, Watanabe N, Buysse DJ, Kaneita Y. Long sleep duration and health  
47  
48 outcomes: A systematic review, meta-analysis and meta-regression. *Sleep Med Rev*  
49  
50 2018; **39**: 25-36.<https://doi.org/10.1016/j.smrv.2017.06.011>  
51  
52  
53 27. Ding D, Rogers K, Macniven R, et al. Revisiting lifestyle risk index assessment in  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 a large Australian sample: should sedentary behavior and sleep be included as  
5  
6 additional risk factors? *Prev Med* 2014; **60**: 102-  
7  
8  
9 [6.https://doi.org/10.1016/j.ypmed.2013.12.021](https://doi.org/10.1016/j.ypmed.2013.12.021)

10  
11  
12 28. Carthy CEM, Yusuf S, Judge C, et al. Sleep Patterns and the Risk of Acute Stroke:  
13  
14 Results from the INTERSTROKE International Case-Control Study. *Neurology* 2023:  
15  
16 10.1212/WNL.0000000000207249.<https://doi.org/10.1212/wnl.0000000000207249>

17  
18  
19 29. Ai S, Zhang J, Zhao G, et al. Causal associations of short and long sleep durations  
20  
21 with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization  
22  
23 analyses in UK Biobank. *Eur Heart J* 2021; **42**(34): 3349-  
24  
25  
26 57.<https://doi.org/10.1093/eurheartj/ehab170>

27  
28  
29  
30 30. Cappuccio FP, Stranges S, Kandala N-B, et al. Gender-Specific Associations of  
31  
32 Short Sleep Duration With Prevalent and Incident Hypertension. *Hypertension* 2007;  
33  
34 **50**(4): 693-700.<https://doi.org/doi:10.1161/HYPERTENSIONAHA.107.095471>

35  
36  
37 31. Meisinger C, Heier M, Löwel H, Schneider A, Döring A. Sleep duration and sleep  
38  
39 complaints and risk of myocardial infarction in middle-aged men and women from the  
40  
41 general population: the MONICA/KORA Augsburg cohort study. *Sleep* 2007; **30**(9):  
42  
43 1121-7.<https://doi.org/10.1093/sleep/30.9.1121>

44  
45  
46 32. Stranges S, Dorn JM, Cappuccio FP, et al. A population-based study of reduced  
47  
48 sleep duration and hypertension: the strongest association may be in premenopausal  
49  
50 women. *Journal of Hypertension* 2010; **28**(5).

51  
52  
53 33. Domínguez F, Fuster V, Fernández-Alvira JM, et al. Association of Sleep Duration  
54  
55 and Quality With Subclinical Atherosclerosis. *J Am Coll Cardiol* 2019; **73**(2): 134-  
56  
57  
58  
59  
60

- 1  
2  
3  
4 44. <https://doi.org/10.1016/j.jacc.2018.10.060>  
5  
6  
7 34. Lovato N, Lack L. Insomnia and mortality: A meta-analysis. *Sleep Medicine*  
8  
9 *Reviews* 2019; **43**: 71-83. <https://doi.org/https://doi.org/10.1016/j.smrv.2018.10.004>  
10  
11  
12 35. Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of  
13  
14 cardiovascular disease: a meta-analysis. *Eur J Prev Cardiol* 2014; **21**(1): 57-  
15  
16  
17 64. <https://doi.org/10.1177/2047487312460020>  
18  
19  
20 36. Sun L, Li K, Zhang Y, Zhang L. Sleep-related healthcare use prevalence among  
21  
22 adults with insomnia symptoms in Hebei, China: a population-based cross-sectional  
23  
24 study. *BMJ Open* 2022; **12**(8): e057331. <https://doi.org/10.1136/bmjopen-2021-057331>  
25  
26  
27 37. Bartlett DJ, Marshall NS, Williams A, Grunstein RR. Predictors of primary  
28  
29 medical care consultation for sleep disorders. *Sleep Med* 2008; **9**(8): 857-  
30  
31  
32 64. <https://doi.org/10.1016/j.sleep.2007.09.002>  
33  
34  
35 38. Morin CM, LeBlanc M, Bélanger L, Ivers H, Mérette C, Savard J. Prevalence of  
36  
37 insomnia and its treatment in Canada. *Can J Psychiatry* 2011; **56**(9): 540-  
38  
39  
40 8. <https://doi.org/10.1177/070674371105600905>  
41  
42  
43 39. Leng Y, Cappuccio FP, Wainwright NW, et al. Sleep duration and risk of fatal and  
44  
45 nonfatal stroke: a prospective study and meta-analysis. *Neurology* 2015; **84**(11): 1072-  
46  
47  
48 9. <https://doi.org/10.1212/wnl.0000000000001371>  
49  
50  
51 40. Song Q, Liu X, Zhou W, et al. Long Sleep Duration and Risk of Ischemic Stroke  
52  
53 and Hemorrhagic Stroke: the Kailuan Prospective Study. *Scientific Reports* 2016; **6**(1):  
54  
55  
56 33664. <https://doi.org/10.1038/srep33664>  
57  
58  
59 41. Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine:  
60

1  
2  
3  
4 Elsevier/Saunders; 2005.

5  
6  
7 42. Diao T, Liu K, Wang Q, et al. Bedtime, sleep pattern, and incident cardiovascular  
8  
9 disease in middle-aged and older Chinese adults: The dongfeng-tongji cohort study.  
10  
11 *Sleep Med* 2023; **110**: 82-8.<https://doi.org/10.1016/j.sleep.2023.08.002>

12  
13  
14 43. Wang C, Hu B, Rangarajan S, et al. Association of bedtime with mortality and  
15  
16 major cardiovascular events: an analysis of 112,198 individuals from 21 countries in  
17  
18 the PURE study. *Sleep Med* 2021; **80**: 265-  
19  
20  
21  
22 72.<https://doi.org/10.1016/j.sleep.2021.01.057>

23  
24  
25 44. Nikbakhtian S, Reed AB, Obika BD, et al. Accelerometer-derived sleep onset  
26  
27 timing and cardiovascular disease incidence: a UK Biobank cohort study. *Eur Heart J*  
28  
29  
30 *Digit Health* 2021; **2**(4): 658-66.<https://doi.org/10.1093/ehjdh/ztab088>

**Table 1. Baseline characteristics of the study participants by sleep duration and sleep disturbance.**

	Sleep duration			Sleep disturbance*	
	<6 h/d	6-9 h/d	>9 h/d	No	Yes
<b>Men (n=198,190)</b>					
No. of participants	13,682	174,257	10,251	171,958	26,232
Age, years	56.4 (10.6)	52.0 (10.7)	52.6 (11.3)	52.1 (10.7)	54.2 (11.0)
Urban area	5,794 (42.3)	76,472 (43.9)	2,371 (23.1)	75,150 (43.7)	9,487 (36.2)
Middle school and above	6,234 (52.9)	103,359 (58.5)	4,984 (52.6)	101,248 (58.1)	13,329 (55.6)
Married	11,993 (89.6)	163,014 (93.4)	9,421 (92.3)	160,873 (93.5)	23,555 (90.7)
Current smoker <sup>†</sup>	9,255 (68.1)	118,080 (67.8)	7,128 (68.7)	116,614 (67.8)	17,849 (68.3)
Ever-regular drinker <sup>‡</sup>	6,578 (44.6)	72,330 (41.6)	4,087 (42.4)	71,165 (41.5)	11,830 (44.3)
Total physical activity, MET-h/d	22.9 (14.8)	22.7 (15.2)	20.1 (16.5)	22.6 (15.2)	22.8 (15.5)
Daily consumption of					
Fresh vegetables	12,988 (94.1)	165,133 (94.9)	9,861 (95.6)	163,243 (95.0)	24,739 (93.8)

	Sleep duration			Sleep disturbance*	
	<6 h/d	6-9 h/d	>9 h/d	No	Yes
Fresh fruits	1,598 (11.1)	25,251 (14.3)	964 (14.4)	24,869 (14.2)	2,944 (12.7)
Red meat	4,234 (29.8)	58,397 (33.0)	2,456 (35.5)	57,236 (32.9)	7,851 (32.5)
Body mass index, kg/m <sup>2</sup>	23.1 (3.2)	23.4 (3.2)	23.4 (3.3)	23.4 (3.2)	23.0 (3.2)
Prevalent hypertension	5,134 (34.7)	62,110 (35.9)	3,982 (37.7)	61,491 (36.0)	9,735 (35.6)
Prevalent diabetes	880 (5.7)	8,692 (5.0)	513 (5.9)	8,624 (5.0)	1,461 (5.5)
Family history of heart attack	390 (3.1)	5,490 (3.1)	317 (3.3)	5,281 (3.0)	916 (3.8)
Family history of stroke	2,271 (17.5)	30,994 (17.9)	1,965 (16.9)	30,245 (17.6)	4,985 (19.3)
<b>Women (n=285,194)</b>					
No. of participants	25,032	245,860	14,302	233,720	51,474
Age, years	56.4 (10.1)	50.6 (10.2)	48.9 (10.4)	50.3 (10.3)	54.0 (10.3)
Urban area	10,682 (42.7)	110,215 (44.8)	3,389 (23.7)	104,466 (44.7)	19,820 (38.5)
Middle school and above	8,044 (39.4)	109,563 (43.8)	5,796 (41.0)	105,440 (43.5)	17,963 (42.0)

	Sleep duration			Sleep disturbance*	
	<6 h/d	6-9 h/d	>9 h/d	No	Yes
Married	20,517 (87.9)	221,770 (89.8)	13,146 (89.5)	211,306 (89.9)	44,127 (88.3)
Current smoker <sup>†</sup>	1,494 (2.7)	5,887 (2.7)	301 (3.2)	5,538 (2.7)	2,144 (2.8)
Ever-regular drinker <sup>‡</sup>	1,239 (3.1)	6,725 (2.9)	375 (3.1)	6,301 (2.8)	2,038 (3.2)
Total physical activity, MET-h/d	21.0 (11.8)	20.9 (12.9)	18.4 (12.5)	20.8 (12.8)	20.9 (12.6)
Daily consumption of					
Fresh vegetables	23,663 (93.9)	232,315 (94.6)	13,775 (94.9)	221,426 (94.7)	48,327 (94.1)
Fresh fruits	4,523 (17.9)	53,828 (21.5)	2,260 (23.6)	51,723 (21.5)	8,888 (20.2)
Red meat	6,153 (23.9)	66,734 (26.7)	2,775 (29.9)	63,242 (26.6)	12,420 (26.4)
Body mass index, kg/m <sup>2</sup>	23.4 (3.5)	23.8 (3.4)	23.9 (3.5)	23.8 (3.4)	23.3 (3.4)
Prevalent hypertension	9,468 (31.3)	77,576 (32.2)	4,900 (34.5)	73,369 (32.4)	18,575 (31.7)
Prevalent diabetes	1,902 (5.8)	13,135 (5.5)	802 (6.4)	12,465 (5.5)	3,374 (5.8)
Family history of heart attack	710 (3.0)	7,900 (3.2)	400 (3.1)	7,309 (3.1)	1,701 (3.7)

	Sleep duration			Sleep disturbance*	
	<6 h/d	6-9 h/d	>9 h/d	No	Yes
Family history of stroke	4,461 (17.5)	42,663 (17.5)	2,777 (17.3)	40,392 (17.2)	9,509 (19.0)
Postmenopausal	18,354 (52.5)	120,489 (50.6)	5,876 (50.0)	111,459 (50.4)	33,260 (52.2)

MET-h/d indicates the metabolic equivalent of tasks hours/day.

All variables were presented as mean (standard deviation) or number (percentage).

Baseline characteristics were adjusted for age and study area, except in the cases where age or urban/rural residence was the variable of interest.

\*Sleep disturbance includes having difficulties initiating and maintaining sleep, early morning awakening, and daytime dysfunction. Participants who reported having one or more of the three aforementioned conditions were classified as having sleep disturbance.

†Participants who had stopped smoking due to illness were included.

‡Regular drinking refers to weekly consumption of any volume of alcohol.

## Figure legends

### **Figure 1. Multivariable-adjusted hazard ratios (95% confidence intervals) for each transition by sleep duration and sleep disturbance in men.**

PYs indicate person-years. HR, hazard ratio; CI, confidence interval.

The definition of sleep disturbance was the same as in Table 1.

Multivariable models were adjusted for attained age, study areas (10 groups), education (no formal school, primary school, middle school, high school, college or university or higher), marital status (married, separated/divorced/widowed/never married), family history of cardiovascular disease (presence, absence), smoking status (never, former, current), alcohol intake (never, former, current weekly), physical activity (metabolic equivalent of tasks hours/day), dietary factors (intake frequency of fresh vegetables, fresh fruits, and red meat; the midpoint value of each frequency category was used in the model and treated as continuous), body mass index ( $\text{kg}/\text{m}^2$ ), and mutually adjusted for sleep duration and sleep disturbance.

### **Figure 2. Multivariable-adjusted hazard ratios (95% confidence intervals) for each transition by sleep duration and sleep disturbance in women.**

PYs indicate person-years. HR, hazard ratio; CI, confidence interval.

The definition of sleep disturbance was the same as in Table 1.

Multivariable models were adjusted for attained age, study areas, education, marital status, family history of cardiovascular disease, menopausal status, smoking status, alcohol intake, physical activity, dietary factors, body mass index, and mutually

1  
2  
3  
4 adjusted for sleep duration and sleep disturbance.  
5  
6  
7  
8

9 **Figure 3. Life expectancy at age 40 years with and without disease by sleep**  
10 **duration and sleep disturbance in men.**  
11  
12

13  
14 LE indicates life expectancy; CI, confidence interval; DFLE, disease-free life  
15 expectancy; %DFLE represents the percentage of disease-free life expectancy to total  
16 life expectancy. The definition of sleep disturbance was the same as in Table 1.  
17  
18  
19  
20  
21  
22  
23  
24

25 **Figure 4. Life expectancy at age 40 years with and without disease by sleep**  
26 **duration and sleep disturbance in women.**  
27  
28

29  
30 LE indicates life expectancy; CI, confidence interval; DFLE, disease-free life  
31 expectancy; %DFLE represents the percentage of disease-free life expectancy to total  
32 life expectancy. The definition of sleep disturbance was the same as in Table 1.  
33  
34  
35  
36  
37  
38  
39

40 **Figure 5. Life expectancy at age 40 years with and without disease by joint**  
41 **categories of sleep duration and sleep disturbance in men and women separately.**  
42  
43  
44

45 LE indicates life expectancy. The definition of sleep disturbance was the same as in  
46 Table 1.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Multivariable-adjusted hazard ratios (95% confidence intervals) for each transition by sleep duration and sleep disturbance in men.

PYs indicate person-years. HR, hazard ratio; CI, confidence interval.

The definition of sleep disturbance was the same as in Table 1.

Multivariable models were adjusted for attained age, study areas (10 groups), education (no formal school, primary school, middle school, high school, college or university or higher), marital status (married, separated/divorced/widowed/never married), family history of cardiovascular disease (presence, absence), smoking status (never, former, current), alcohol intake (never, former, current weekly), physical activity (metabolic equivalent of tasks hours/day), dietary factors (intake frequency of fresh vegetables, fresh fruits, and red meat; the midpoint value of each frequency category was used in the model and treated as continuous), body mass index (kg/m<sup>2</sup>), and mutually adjusted for sleep duration and sleep disturbance.

177x165mm (300 x 300 DPI)




Figure 2. Multivariable-adjusted hazard ratios (95% confidence intervals) for each transition by sleep duration and sleep disturbance in women.

PYs indicate person-years. HR, hazard ratio; CI, confidence interval.

The definition of sleep disturbance was the same as in Table 1.

Multivariable models were adjusted for attained age, study areas, education, marital status, family history of cardiovascular disease, menopausal status, smoking status, alcohol intake, physical activity, dietary factors, body mass index, and mutually adjusted for sleep duration and sleep disturbance.

177x165mm (300 x 300 DPI)





Figure 3. Life expectancy at age 40 years with and without disease by sleep duration and sleep disturbance in men. LE indicates life expectancy; CI, confidence interval; DFLE, disease-free life expectancy; %DFLE represents the percentage of disease-free life expectancy to total life expectancy. The definition of sleep disturbance was the same as in Table 1.

159x109mm (300 x 300 DPI)



159x109mm (300 x 300 DPI)




Figure 5. Life expectancy at age 40 years with and without disease by joint categories of sleep duration and sleep disturbance in men and women separately. LE indicates life expectancy. The definition of sleep disturbance was the same as in Table 1.

199x122mm (300 x 300 DPI)